UK markets open in 4 hours 4 minutes

Puma Biotechnology, Inc. (PBYI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.810.00 (0.00%)
At close: 4:00PM EDT
9.81 0.00 (0.00%)
After hours: 04:01PM EDT

Puma Biotechnology, Inc.

10880 Wilshire Boulevard
Suite 2150
Los Angeles, CA 90024
United States
424 248 6500
http://www.pumabiotechnology.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees267

Key executives

NameTitlePayExercisedYear born
Mr. Alan H. AuerbachFounder, Chairman, Pres, CEO & Sec.5.69MN/A1970
Mr. Maximo F. NouguesCFO & Principal Accounting Officer1.63MN/A1969
Mr. Douglas Hunt B.Sc., FRAPSSr. VP of Regulatory Affairs, Medical Writing & Project Management2.14MN/A1965
Mr. Jeffrey Jerome LudwigChief Commercial Officer4.61MN/A1966
Mr. Mariann OhanesianSr. Director of Investor RelationsN/AN/AN/A
Charon Spencer Sr.VP of HRN/AN/AN/A
Dr. Alvin F. WongSr. VP of Clinical Science & PharmacologyN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Corporate governance

Puma Biotechnology, Inc.’s ISS governance QualityScore as of 1 June 2021 is 4. The pillar scores are Audit: 8; Board: 6; Shareholder rights: 3; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.